Genenta Science is a clinical stage immuno-oncology company developing a cell-based platform that harnesses the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. The platform is not restricted by tumor type or target antigen and enables sustained targeted expression of therapeutic payloads inside the tumor microenvironment.

Genenta Science

Mapi Pharma is a clinical stage pharmaceutical company that develops complex active pharmaceutical ingredients and proprietary pharmaceuticals, including long acting depot injectable drugs.

Mapi Pharma

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Immunocore Holdings plc American Depositary Shares

Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. 

See our community guidelines: http://bit.ly/2kFA8hr

Oxford Finance LLC

General Atlantic

Rock Springs Capital

RTW Investments

WuXi AppTec

Bill & Melinda Gates Foundation

Terra Magnum Capital Partners (""""TMCP"""")""

CCB International

JDRF T1D Fund

BlackRock

Immunocore

Unhealthy cells have evolved mechanisms for evading T cells, making diseases like cancer harder to treat. 

ImmTAC molecules contain a T cell receptor that has been engineered to better recognise its target and seek out evading cells. #IMCRSharing #innovation

It is by living our values daily that we are able to develop transformative treatments and to innovate for patients. #WeAreIMCR #innovation #ResearchAndDevelopment

Looking to advance your career in Regulatory Affairs? Apply for our Regulatory Submissions Manager position and grow within a highly innovative, agile, and entrepreneurial environment. https://lnkd.in/eu7WxW_v #WeAreIMCR #hiring #biotechjobs

Gynecologic cancers account for nearly 40% of cancer cases & 1/3 of cancer deaths in women. We must continue the search for new treatments & prevention measures to save the lives of women across the globe. #CervicalCancerPreventionWeek #CervicalCancerAwarenessMonth #WeAreIMCR

Come and apply the principles of effective clinical project practices at a pioneering biotech. #WeAreIMCR #biotechjobs #hiring
https://lnkd.in/eTSVJJcC

Metric
Company Name	Genenta Science	Mapi Pharma
Symbol
MSH ID	COM:GENENTA	COM:MAPI-PHARMA
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	IT	IL
Stage
Employee Count
Website	genenta.com	mapi-pharma.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:IMMUNOCORE

Immunocore Holdings plc

Last Close

32.12

22/11 21:00

Market Cap

1.62B

Beta: -

Volume Today

190.00K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue